Clinical trial outsourcing is undergoing rapid transformation as sponsors, CROs, and biotech firms adapt to shifting market dynamics, regulatory hurdles, and geopolitical uncertainty. This article distills actionable insight from a live Clinical Outsourcing Group (COG) Europe session featuring senior leaders, including Heike Schoen of Lumis International, on how to build resilient strategies for global clinical study optimization.

This session, recorded at COG Europe in Amsterdam, brings together clinical research decision-makers to dissect the evolving landscape of clinical trial outsourcing. Heike Schoen, CEO at Lumis International, draws from multi-year experience partnering with CROs and sponsors to deliver drug development programs worldwide. Her focus: the tangible changes in CRO partnerships, operational models, and risk factors shaping clinical trial location decisions.

The session is part of The PBC Group’s commitment to actionable, real-world content for clinical operations leaders.

Outsourcing in Clinical Trials: Market Growth and Trends

Clinical trial outsourcing continues to expand, with estimates that the global outsourcing market will reach around $87 billion within nine years, growing at a compound annual rate of 5.5–7%. The clinical trials market overall is predicted to reach $160 billion by 2033. This growth signals sustained demand, driven by drug innovation and the increasing complexity of study designs.

Outsourcing trends reflect a shift toward geographic diversification and specialization. Emerging markets such as Asia-Pacific and Latin America are attracting more trials, thanks to their large patient pools, cost-competitive environments, and evolving regulatory frameworks. Meanwhile, Europe has seen a decline in new studies, largely attributed to higher operational costs and regulatory complexity.

Another notable trend is the influx of “virtual biotech” companies—smaller players seeking specialized support due to limited internal resources. Sponsors increasingly expect CROs to offer deeper therapeutic expertise and flexibility, especially as the integration of data analytics and artificial intelligence (AI) becomes essential to modern trial operations.

CRO Partnerships: Evolution from Transactional to Hybrid Models

Traditionally, CRO partnerships were transactional, providing specific outsourced functions on a per-project basis. Over time, strategic alliances became common, with preferred providers working across drug development pipelines. Today, sponsors are moving toward hybrid outsourcing models—modular arrangements in which some functions are retained in-house and others delegated to the CRO.

Large pharma companies in particular are recruiting back in-house expertise, blending full-service and functional service provider (FSP) models from the same CRO. These hybrid setups seek to optimize resources, improve trial flexibility, and adapt to increasingly specialized therapeutic needs.

Case studies shared in the session highlight the benefits:

• Novartis and PPD: A functional service partnership allowed Novartis’s internal team to work closely with PPD specialists in monitoring, data management, and statistical analysis. The result: enhanced flexibility, faster trial execution, and a model well-suited to complex areas such as oncology.

• Moderna and Medidata: Leveraging Medidata’s digital platform enabled decentralized trial innovations—remote electronic consent, virtual visits, centralized data—and incorporated AI for real-time data monitoring and protocol optimization. This “digital-first” CRO partnership improved patient access and enabled design scalability.

  
  

Increasingly, sponsors require CROs to be not just generalists, but also therapeutic area experts, notably in emerging modalities like cell and gene therapy. Partnerships now emphasize flexibility, scalability, and risk-sharing contracts indexed to performance KPIs and milestones.

Geographic Diversification: Opportunities and Risks

Global clinical outsourcing strategies increasingly hinge on the selection of trial locations, with operational and regulatory risk profiles shaping site choice and CRO selection.

Top destinations currently include:

• China (over 10,000 trials initiated, mostly domestically run)

• United States (6,000 studies)

• Japan and Europe/UK (declining numbers, driven by cost and regulatory burden)

Cost effectiveness, patient recruitment speed, and infrastructure quality differentiate regions like Asia-Pacific, Latin America, and Africa, which are seeing growth in trial activity. Europe’s share has contracted, raising concern over reduced patient access—particularly for rare disease populations, where participation may be the only care alternative.

Geopolitical instability further complicates location strategy. Recent events, such as the Russia-Ukraine war, forced sponsors and CROs to relocate studies mid-stream, often to countries with unfamiliar infrastructure or processes. Contingency planning for geographic disruption, regulatory shifts, supply chain fragility (e.g., border closures, customs delays), and data governance are now essential components of risk management.

Emerging regions also vary in digital trial readiness—a key factor as decentralized and technology-driven studies proliferate. Investment in digital infrastructure and training remains a priority for sponsor and CRO operational optimization.

The Impact of Technology and AI on CRO Value Pools

Digital transformation and AI are accelerating operational efficiency across the clinical outsourcing landscape. According to Boston Consulting, AI may disrupt up to 30% of the traditional CRO value chain. Examples include:

• Clinical monitoring: 30–50% of conventional monitoring processes are projected to be standardized via AI tools, freeing human resources for higher-value tasks.

• Medical writing: Up to 70% of document drafting is now automatable, allowing teams to focus on interpretation and statistical analysis.

Sponsors expect CROs to adapt swiftly to technology innovations, integrating digital platforms for real-time data oversight and protocol optimization. The transition generates new service streams and revenue possibilities, but also raises the bar for change agility—a key CRO selection criterion.

Equally critical is data privacy management. Global regulations like GDPR in Europe, HIPAA in the US, and emerging local requirements in China and India necessitate careful cross-border governance. CROs must now demonstrate robust data management practices and jurisdictional expertise to remain competitive.

What This Means in Practice

• Audit CROs for both therapeutic expertise and capability to provide flexible service models (full-service, FSP, or hybrid).

• Incorporate geopolitical risk and contingency planning into location strategy and vendor selection.

• Benchmark vendor agility: How quickly can they adapt to regulatory or operational disruptions?

• Evaluate digital infrastructure and AI readiness, ensuring sites and CROs are prepared for decentralized trial needs.

• Structure contracts around risk-sharing, with KPIs tied to performance and milestone delivery.

• Scrutinize data privacy policies and ability to manage cross-border data with full regulatory compliance.

• Assess supply chain robustness—biological sample shipment, customs processes, and alternative routing capacity.

Key Takeaways

1. Hybrid outsourcing models are overtaking traditional structures, combining in-house and CRO expertise for greater flexibility and efficiency.

2. Location selection now hinges largely on geopolitical stability, regulatory environment, and operational resilience.

3. Sponsors increasingly value CROs with deep therapeutic specialization, multi-jurisdictional experience, and strong digital capabilities.

4. Technology and AI are redefining core CRO functions, demanding adaptability and investment in digital approaches.

5. Proactive risk management—from regulation to supply chain—is essential to prevent disruption and optimize clinical study outcomes.

Selected Quotes

“Sponsors expect CROs to be more specialized with their expertise… This is a different way of partnering, with deep knowledge in the chosen area.”— Heike Schoen

“The contingency planning for a potential geographic disruption should be part of the risk management… To have alternatives in place.”— Heike Schoen

“AI will disrupt 30% of the CRO’s traditional value pools… In monitoring, 30 to 50% will be changed through standardization. The biggest one is medical writing—up to 70% now standardizable.”— Heike Schoen

“Location strategy matters more than ever before. Political and regulatory stability are now core factors in site and CRO selection.”— Heike Schoen

Links & References

• The PBC Group: https://thepbcgroup.com

• COG Meeting Series and content library: https://www.thepbcgroup.com/blog